Stock comparison

BIIBvsREGN

Biogen IncvsRegeneron Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BIIB

Biogen Inc

$187.88

+6.91%

Biotechnology$25.8BNASDAQ

REGN

Regeneron Pharmaceuticals Inc

$766.02

+3.34%

Biotechnology$79.2BNASDAQ

60-day price, rebased to 100

BIIB +6.64% · REGN +1.98%

Round-by-round

BIIB 3·REGN 3

EdgeBIIB

Valuation upside

+7.40% vs -22.60% to DCF fair value

EdgeREGN

Balance-sheet strength

Altman Z 3.10 vs 7.40

EdgeBIIB

Fundamental quality

Piotroski 6.00 vs 5.00 (of 9)

EdgeREGN

Growth + margins

Rule-of-40 23.00 vs 27.20

EdgeBIIB

60-day momentum

+6.64% vs +1.98% price return

EdgeREGN

Market-cap liquidity

$25.8B vs $79.2B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBIIBorREGN

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.